Latest news with #bio-based
Yahoo
29-07-2025
- Business
- Yahoo
Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand
The Freepod® nasal spray pump, globally used with the Otrivin® brand, is now made from 52% bio-based feedstock CRYSTAL LAKE, Ill., July 29, 2025--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. Reinforcing circularity in pharmaceutical packaging Aptar Pharma's Freepod® spray pump used with Haleon's Otrivin® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device. ISCC PLUS certified manufacturing and supply chain Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod® components. Partnership for a more sustainable approach The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin® Freepod® winning the World Packaging Award in 2019 for its innovative and sustainable design. The use of bio-based or renewable feedstocks for the Otrivin® products with Freepod® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma's Freepod® for Otrivin®, available globally, demonstrates Aptar's commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon's latest microdroplet technology, which is being rolled out globally since 2023. "At Aptar, sustainability is not just a responsibility - it's a strategic advantage," commented Gael Touya, President of Aptar Pharma. "The launch of Freepod® Futurity™ reflects our commitment to developing solutions that respond to consumers' increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient." With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals. *ISCC Plus certified bio-based feedstock, mass balance approach.**The end point for the goal delivery period is the end of the 2025 calendar year. About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding. View source version on Contacts Media Contact: Ciara JacksonAptar Pharma+49 151 1951
Yahoo
17-06-2025
- Business
- Yahoo
AFYREN Begins New Phase of Industrial Strategy as First Plant AFYREN NEOXY Achieves Continuous Production
AFYREN NEOXY: continuous production achieved and acceleration in commercialization Industrial continuous running1 of all stages of the process validated in recent weeks and start of industrial ramp-up Hundreds of tons of bio-based acids produced and currently being commercialized €165 million in revenue secured by contracts, to be executed in coming years Update on short and medium-term objectives AFYREN NEOXY: objective to achieve significant production revenue in 2025, estimated in the low single-digit million euros range2, and plant break-even3 targeted within a few quarters AFYREN: aims to achieve the goal of building and operating three plants in a sequence manner to better capitalize on the success of AFYREN NEOXY, including intermediary debottlenecking project4 CLERMONT-FERRAND, France & LYON, France, June 17, 2025--(BUSINESS WIRE)--Regulatory News: AFYREN (Paris:ALAFY), a greentech company offering industrial customers bio-based, low-carbon products through its unique fermentation technology based on a circular model, today announced its first plant AFYREN NEOXY has achieved continuous production, enabling the acceleration of commercialization. Nicolas SORDET, CEO AFYREN, declares: "The transition to continuous production at AFYREN NEOXY, the first biorefinery using the AFYREN technology, demonstrates our command of all key stages of an innovative process with no equivalents worldwide. This major success marks the end of an especially demanding period for our teams, whose dedication and resilience I sincerely commend. We are now in the industrial ramp-up phase, enabling us to regularly deliver finished products to our customers in increasing volumes. Building on this success, we are planning to increase our industrial capacity production gradually in coming quarters, in order to better capitalize on AFYREN NEOXY." Continuous production achieved and acceleration in commercialization AFYREN has successfully manufactured hundreds of tons of products in recent weeks, resulting from continuous production at the plant. The bio-based acids produced are currently undergoing qualification prior to delivery, in accordance with the multi-year contracts signed with customers. This major milestone is the culmination of two years of efforts by the AFYREN and AFYREN NEOXY teams to ensure the reliability of the equipment and mastering the operating conditions at industrial scale, ensuring the continuous operation of this unique biorefinery. This milestone marks the beginning of a new phase that will see the gradual ramp-up of AFYREN NEOXY's industrial production to ultimately achieve the targets set in 2021: annual production revenue of around €35 million with a current EBITDA margin of around 25% (equivalent to a current EBITDA of around €9 million) at full capacity (16,000 tons per year). During the ramp-up period, product shipment will be made on a regular basis with priority given to long-term customers. As a reminder, commercial commitments secured through contracts represent cumulative revenue of over €165 million, to be recognized in the upcoming years. These contracts are with leading players in the target markets of human nutrition and feed, flavors and fragrances, life sciences, materials sciences, and lubricants. Update on short and medium-term objectives On this basis, AFYREN NEOXY expects production revenue in 2025 to be in the low single-digit million euros range5. The plant is expected to break even (positive current EBITDA) within a few quarters. In parallel, AFYREN is planning targeted investments to lift bottlenecks6 at the AFYREN NEOXY plant. By doing so, AFYREN would increase production capacity and boost target profitability beyond the previously mentioned objectives. AFYREN's medium-term objectives will be updated to reflect the progress of the AFYREN NEOXY ramp-up. The core operational and financial targets remain unchanged — specifically the plan to build and operate three production sites, generating a combined €150 million in revenue at full capacity7 with a target Group EBITDA margin of around 30%. Instead of adhering strictly to the current target of having three plants installed, of which two in continuous production by 2028, AFYREN is exploring a phased approach. This would allow the company to consolidate the achievements of its first biorefinery and leverage the operational experience gained before moving forward with the development of Plants 2 and 3. This approach will enable the Group to maintain a safe degree of agility and keep good control of AFYREN's cash burn and should enable the financing of future plants under optimized conditions. Stefan BORGAS, Chairman of AFYREN's Board of Directors, added: "The transition to continuous production is a major milestone in AFYREN's history. The Company is joining a very select group of companies that have successfully industrialized a competitive green technology. This is a remarkable achievement in the increasingly demanding and selective chemical industry. It opens up extremely positive prospects for our company in terms of industrial and commercial development." About AFYREN AFYREN is a French greentech company, founded in 2012, focused on providing innovative, sustainable solutions to reduce reliance on fossil-based resources. AFYREN's proprietary, nature-inspired fermentation technology valorizes local biomass from non-food agricultural co-products to produce 100% biobased, low-carbon carboxylic acids. The company's sustainable solutions address decarbonization challenges in a wide variety of strategic sectors, including human and animal nutrition, flavors and fragrances, life sciences, materials science, plus lubricants and technical fluids. AFYREN's competitive, plug-and-play, circular technology enables manufacturers to adopt sustainable solutions without modifying production processes. The company's first industrial plant, AFYREN NEOXY, a joint venture with Bpifrance's SPI fund, is based in the Grand-Est region of France, serving primarily the European market. AFYREN is also pursuing a project in Thailand with a global leader in the sugar industry and is building its presence in the Americas, based on existing distribution agreements. At the end of 2024, AFYREN employed 130 people across sites in Lyon, Clermont-Ferrand and Carling Saint-Avold. Committed to continuous innovation, the company invests 20% of its annual budget in R&D to further develop the range of sustainable solutions. AFYREN is listed on Euronext Growth® Paris since 2021 (ISIN code: FR0014005AC9, ticker: ALAFY). For more information, visit and follow us on LinkedIn. Financial calendar Events Dates Annual General Meeting Tuesday, June 17, 2025, in Lyon 2025 half-year results Thursday, September 25, 2025 1 Simultaneous operation of all stages of the process – from fermentation to finished products, in a stable and repeatable manner2 Projections subject to operational adjustments to be made to increase production rates during the ramp-up phase3 Positive current EBITDA from production4 Removal of capacity bottlenecks identified in the operations chain, enabling increased production capacity and reliability of operations with a higher target profitability for AFYREN NEOXY5 Projections subject to operational adjustments to be made to increase production rates during the ramp-up phase6 Removal of capacity bottlenecks identified in the operations chain, enabling increased production capacity and reliability of operations with a higher target profitability for AFYREN NEOXY7 After a ramp-up period View source version on Contacts AFYRENDirector for ESG, Communications and Public AffairsCaroline Investor RelationsMark Reinhardinvest@ NewCapInvestor RelationsThéo Martin / Mathilde BohinTel: +33 1 44 71 94 94afyren@ Media RelationsNicolas Mérigeau / Gaëlle FromaigeatTel: +33 1 44 71 94 98afyren@ MC Services AG (international)Investor RelationsBettina EllinghorstMedia RelationsShaun Brown, Dr. Johanna KoblerTel: +49 89 210 228 0afyren@ Sign in to access your portfolio
Yahoo
06-05-2025
- Business
- Yahoo
Celebrating 15 Years of I'm green™ Bio-Based With Operation Rates Above Nameplate Capacity After Expansion
Braskem celebrates 15 years of I'm green bio-based Braskem has reached 275,000 tons/year of green ethylene, 37% above the production capacity compared to the initial project in 2010 PHILADELPHIA, May 06, 2025--(BUSINESS WIRE)--Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), a global market leader and pioneer producer of bio-polyethylene, proudly celebrates the 15th anniversary of its groundbreaking I'm green™ bio-based portfolio. In line with this milestone, Braskem is reinforcing its strategic focus on further developing the I'm green™ bio-based offerings and its unwavering commitment to supporting the industry and brand owners in their sustainability journey. Braskem begins celebrating 15 years as a producer of the I'm green™ bio-based portfolio by celebrating the 37% expansion in production capacity at the green ethylene unit in Triunfo, Rio Grande do Sul, Brazil. Now, our production capacity is 275,000 tons/year of green ethylene, which is the raw material used in the production of Braskem's I'm green™ bio-based polyethylene. In 2010, when we started operations, our capacity of green ethylene was 200,000 tons/year. Green ethylene offers the same quality and versatility as fossil-based products, but with the added benefit of capturing about two tons of carbon dioxide for every ton produced, measured throughout its production chain up to Braskem's gate. This additional capacity in biopolymer production will represent the capture of approximately 159,000 tons of CO₂ per year, equivalent to the carbon emitted by 12,000 U.S. citizens in one year. "In 2025, as we celebrate the anniversary of our pioneering I'm green™ bio-based brand, we reflect on the remarkable journey we've undertaken in advancing sustainable plastics and chemicals. This milestone is not just a testament to our innovation and leadership in biopolymers but also a celebration of our commitment to a sustainable future. The expansion of our bio-ethylene unit in 2023 was a significant step forward in our mission to support the industry and brand owners on the sustainability journey, and it brings us closer to our goal of becoming carbon-neutral by 2050. We are proud of what we've achieved and are excited about the future possibilities," says Walmir Soller, Vice President for North America, Europe, and Asia – NAMEA and CEO of Braskem BV. Since the inauguration of the bio-ethylene plant in 2010, Braskem has achieved numerous milestones. Braskem shares its groundbreaking developments on the I'm green™ bio-based website. To learn more, visit
